EGFR and non-small cell lung carcinoma: Together, these results suggest that the OS of advanced EGFR-mutated NSCLC patients who received bevacizumab in combination with 1st/2nd-generation EGFR-TKIs or afatinib alone followed by second-line osimertinib is not inferior to that of patients who received first-line osimertinib therapy.